Treatment Recommendations for Clostridioides difficile Infection

Initial Episode Management

• Fidaxomicin 200 mg orally twice daily for 10 days is the preferred first‑line regimen for an initial CDI episode in adults, because it demonstrates superior efficacy in preventing recurrence compared with vancomycin. 1
• Vancomycin 125 mg orally four times daily for 10 days is an acceptable alternative when fidaxomicin is unavailable or cost‑prohibitive. 1
• Metronidazole is no longer recommended as a first‑line agent when fidaxomicin or vancomycin can be used. 1
• Disease severity is no longer used to stratify initial‑episode therapy; the same first‑line agents are recommended regardless of severity. 1
• Non‑severe CDI is defined by a white‑blood‑cell count ≤ 15,000 cells/µL and serum creatinine < 1.5 mg/dL. 1

Recurrence Management

First Recurrence

• Fidaxomicin 200 mg orally twice daily for 10 days (standard) or a 5‑day BID course followed by every‑other‑day dosing for 20 days (extended regimen) is recommended for the first recurrence. 1
• A tapered‑and‑pulsed vancomycin regimen (125 mg orally four times daily for 10–14 days, then twice daily for 7 days, once daily for 7 days, then every 2–3 days for 2–8 weeks) is an alternative strategy. [1][2]
• If metronidazole was used for the initial episode, a standard vancomycin course (125 mg orally four times daily for 10 days) is appropriate. 1

Subsequent Recurrences (≥ 2)

• Fidaxomicin (standard 10‑day or extended regimen) remains an option. 1
• The tapered‑and‑pulsed vancomycin regimen can be reused. [1][2]
• Vancomycin 125 mg orally four times daily for 10 days followed by rifaximin 400 mg orally three times daily for 20 days is a recommended combination. 1
• Fecal microbiota transplantation (FMT) is advised after at least two recurrences (i.e., three total CDI episodes) when adequate antibiotic courses have been attempted. 1

Severe/Complicated (Fulminant) CDI

• High‑dose oral (or nasogastric) vancomycin 500 mg four times daily is indicated for fulminant disease. 1
• If ileus is present, add rectal vancomycin 500 mg diluted in 100–500 mL normal saline every 6 hours. 1
• Intravenous metronidazole 500 mg every 8 hours should be administered concurrently with oral/rectal vancomycin. 1

Adjunctive Therapies

• Bezlotoxumab 10 mg/kg IV as a single dose should be given during antibiotic therapy to patients at high risk of recurrence (e.g., older adults or those with prior treatment failures). 2
• Caution is advised when using bezlotoxumab in patients with congestive heart failure due to an increased risk of adverse events. [1][2]

Implementation Considerations

Common Pitfalls

• Intravenous vancomycin alone is ineffective for CDI because it does not achieve therapeutic colonic concentrations. 2
• Oral vancomycin should be continued for at least 5 days after any concurrent systemic antibiotics are stopped to avoid premature discontinuation. 2
• The tapered‑and‑pulsed regimen uses 125 mg doses throughout; higher 500 mg doses are reserved only for fulminant disease. 2
• During the pulse phase, dosing occurs every 2–3 days rather than daily; clear patient counseling is essential. 2

Monitoring

• Renal function should be monitored throughout extended oral vancomycin courses, especially in older adults, because inflamed intestinal mucosa can allow measurable serum vancomycin levels. 2

Safety Alerts for Fecal Microbiota Transplantation

• FDA safety alerts (since 2019) have documented transmission of pathogenic organisms—including multidrug‑resistant E. coli and SARS‑CoV‑2—from donor to recipient, with some cases resulting in death. 1
• FMT should be performed only after rigorous donor and specimen screening in accordance with FDA recommendations. 1

Rationale for De‑emphasizing Metronidazole

• Metronidazole has been removed from first‑line recommendations in major international guidelines (IDSA/SHEA, ESCMID, Australasian) because it shows inferior efficacy compared with vancomycin and fidaxomicin. 1
• It should be reserved solely for non‑severe CDI when fidaxomicin and vancomycin are truly unavailable. 1

First‑Line Therapy for Initial CDI and Definition of Fulminant CDI

Initial Episode Treatment

Fulminant (Severe‑Complicated) CDI

First‑Line and Recurrence Management of Clostridioides difficile Infection

Initial Episode – First‑Line Therapy

• Fidaxomicin 200 mg orally twice daily for 10 days is the preferred first‑line treatment for all adult patients with an initial CDI episode, irrespective of disease severity. 4
• Vancomycin 125 mg orally four times daily for 10 days is an acceptable alternative when fidaxomicin is unavailable or cost‑prohibitive. 4

First Recurrence

• For a first recurrence, fidaxomicin remains the preferred agent; either the standard 200 mg twice daily for 10 days or an extended regimen of 200 mg twice daily for 5 days followed by 200 mg every other day for 20 days. 4
• Tapered‑and‑pulsed oral vancomycin (125 mg four times daily for 10–14 days, then twice daily for 7 days, once daily for 7 days, then every 2–3 days for 2–8 weeks) is the preferred alternative regimen for a first recurrence. 4
• A standard 10‑day vancomycin course (125 mg four times daily) is appropriate if metronidazole was used for the initial episode. 4

Multiple Recurrences and Fecal Microbiota Transplantation (FMT)

• After ≥2 recurrences (≥3 total CDI episodes), fecal microbiota transplantation should be offered after completing adequate antibiotic trials. [4][5]
• All patients, except those with a known anaphylactic food allergy, should be offered FMT regardless of overall health status. 5
• Universal donors are preferred over related donors, and rigorous donor screening is mandatory to prevent transmission of multidrug‑resistant organisms. 5
• Recipients should be followed for at least 8 weeks to assess efficacy and monitor for adverse events. 5
• Testing for cure by repeat C. difficile detection is not required after FMT unless symptoms persist or relapse is suspected. 5

Fulminant (Severe‑Complicated) CDI

• Fulminant CDI is defined by hypotension/shock, ileus, or toxic megacolon. 4
• Treatment requires high‑dose oral vancomycin 500 mg four times daily (or via nasogastric tube if oral intake is impossible). 4
• If ileus is present, add rectal vancomycin 500 mg in 100–500 mL normal saline every 6 hours. 4
• Concurrent intravenous metronidazole 500 mg every 8 hours must be administered, especially when ileus is present. 4

Adjunctive Therapy – Bezlotoxumab

• A single intravenous dose of bezlotoxumab 10 mg/kg given during antibiotic therapy is recommended for patients at high risk of recurrence (e.g., age > 65 years, immunocompromised status, severe CDI on presentation). 4
• Bezlotoxumab should be used with caution in patients with congestive heart failure because of FDA‑issued safety warnings regarding increased adverse events. 4
• Evidence combining bezlotoxumab with fidaxomicin is limited. 4

Definitions and Additional Considerations

• Non‑severe CDI is defined by a white‑blood‑cell count ≤15,000 cells/µL and serum creatinine <1.5 mg/dL. 4